Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis

BACKGROUND/AIMS: New direct-acting antivirals have shown surprising success in the treatment of hepatitis C, not only in the general population, but also in difficult-to-treat cohorts. However, there is still limited data regarding direct-acting antivirals, including sofosbuvir (SOF), in the context...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Hee Yeon, Seo, Myeong-Sook, Yoon, Sun-Young, Choi, Jong Wook, Ko, Soon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214360/
https://www.ncbi.nlm.nih.gov/pubmed/31064176
http://dx.doi.org/10.3904/kjim.2018.338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214360/
https://www.ncbi.nlm.nih.gov/pubmed/31064176
http://dx.doi.org/10.3904/kjim.2018.338

Ejemplares similares